HomeStartups & VentureArticle
Startups · GlobeNewswire

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

By Arch BiopartnersJuly 17, 2026 · 1 min read

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND IL-32 chronic kidney disease (…

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to acc…

Startups & Venture
Startups · GlobeNewswire
The Sovereign Post
■ More from Startups & Venture